AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.44
-0.04 (-2.70%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.48
Open1.47
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.42 - 1.54
52 Week Range0.79 - 5.17
Volume197,611
Avg. Volume605,683
Market Cap24.049M
Beta1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateFeb 9, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • PR Newswire10 days ago

    Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting

    SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting.  The presentation entitled: "A Broad-Spectrum Platform to Address Life-Threating Viral Infections," is scheduled to begin at 8:30am eastern on February 14th.  The presentation slide-deck will be made available on the Aethlon Medical website at https://www.aethlonmedical.com/news-media/presentations. The American Society for Microbiology Biothreats Meeting is being held today, February 12th through the 14th at the Hilton, Baltimore Md.  The event includes tracks on high consequence pathogen research, biological threat reduction, product development, and policy.

  • Zacks Small Cap Research16 days ago

    AEMD: Q3 Results. Hemopurifier Pathway Could Benefit From New FDA Mindset

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...

  • PR Newswire20 days ago

    Aethlon Medical Announces Fiscal 2018 Third Quarter Results

    SAN DIEGO , Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire24 days ago

    Aethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018

    SAN DIEGO , Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third ...

  • PR Newswirelast month

    Aethlon Medical Announces Validation Completion for European Patent Protecting Methods of Quantifying Exosomes

    SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that validation has completed and the opposition period expired for European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES." The patent was validated in Germany, France, Great Britain, and Spain. In recent years, exosomes have emerged as a significant diagnostic and therapeutic tool for a wide range of disease conditions, including cancer, tuberculosis, Alzheimer's, and chronic traumatic encephalopathy (CTE).

  • Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?
    Simply Wall St.last month

    Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?

    Aethlon Medical Inc (NASDAQ:AEMD), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered, smallRead More...

  • PR Newswirelast month

    Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections

    SAN DIEGO, Jan. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 ("the '418 Application"), entitled "METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS." The allowed claims of the '418 Application embody cartridges for the Aethlon Hemopurifier®, which removes viral particles from the blood or plasma of infected patients.  The '418 Application is a continuation of U.S. Patent Number 7,226,429, which embodies methods of reducing viral loads in the blood of individuals infected with a virus. Together, this intellectual property further protects the Aethlon Hemopurifier® and secures Aethlon's position as a leader in pioneering therapeutic strategies to address viral infections.

  • GlobeNewswirelast month

    Market Trends Toward New Normal in FTD Companies, Acuity Brands, MINDBODY, Actinium Pharmaceuticals, XG Technology, and Aethlon Medical — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD ...

  • PR Newswirelast month

    Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors

    SAN DIEGO, Jan. 10, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Sabrina Martucci Johnson to its Board of Directors and to its Audit Committee. "We are very pleased to have Sabrina join the Aethlon team," stated Aethlon Medical founder and CEO, Jim Joyce.

  • Benzingalast month

    Aethlon Shares Jump Before '60 Minutes' Report On CTE, Vets

    Aethlon Medical (NASDAQ: AEMD ) reportedly plays a part in a “60 Minutes” segment on CTE in combat veterans that’s airing Sunday. The story says combat veterans exposed to bomb blasts are being diagnosed ...

  • How Does Aethlon Medical Inc’s (NASDAQ:AEMD) Earnings Growth Stack Up Against Industry Performance?
    Simply Wall St.2 months ago

    How Does Aethlon Medical Inc’s (NASDAQ:AEMD) Earnings Growth Stack Up Against Industry Performance?

    When Aethlon Medical Inc (NASDAQ:AEMD) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • PR Newswire3 months ago

    Aethlon Medical Names Dr. Charles J. Fisher Chairman of the Board

    SAN DIEGO, Nov. 29, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD as Chairman of its Board of Directors. "We are truly appreciative that Chuck has agreed to expand his role within our organization," stated Aethlon founder & CEO Jim Joyce. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections.

  • What Investors Should Know About Aethlon Medical Inc’s (AEMD) Financial Strength
    Simply Wall St.3 months ago

    What Investors Should Know About Aethlon Medical Inc’s (AEMD) Financial Strength

    While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of USD $14.62M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • PR Newswire3 months ago

    Dr. Charles J. Fisher, Jr. Joins Aethlon Medical's Board of Directors

    SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Charles ("Chuck") J. Fisher, Jr., MD to its Board of Directors and to its Audit Committee. Dr. Fisher qualifies as an independent director under the Nasdaq Rules, and his appointment fills an open Board seat. Dr. Fisher is a physician scientist with a distinguished career in both academia and industry spanning over 30 years.

  • Zacks Small Cap Research3 months ago

    AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway

    Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018.  Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike).  AEMD expects current cash (i.e.

  • PR Newswire4 months ago

    Aethlon Medical Announces Fiscal 2018 Second Quarter Results

    SAN DIEGO , Nov. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • ACCESSWIRE4 months ago

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern ...

  • ACCESSWIRE4 months ago

    Featured Company News - iBio Announces Large-Scale Manufacturing Collaboration with Aethlon Medical

    LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for iBio, Inc. (NYSE: IBIO ), following which we have published a ...

  • PR Newswire4 months ago

    Aethlon Medical Announces Large-Scale Production Collaboration

    SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®.  iBio is a leading developer of plant-based biopharmaceuticals. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

  • How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?
    Simply Wall St.4 months ago

    How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?

    Aethlon Medical Inc (NASDAQ:AEMD), a USD$14.64M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • PR Newswire4 months ago

    Aethlon Medical to Present at the 2017 BIO Investor Forum

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 2017 BIO Investor Forum in San Francisco, CA on October 18, 2017, at 2:15pm (pacific time) at the Westin St. Francis Hotel. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website at  http://www.aethlonmedical.com/news-media/presentations. Aethlon Medical is focused on addressing unmet needs in global health and biodefense.

  • PR Newswire4 months ago

    Aethlon Medical Announces Compliance With Nasdaq Listing Criteria

    SAN DIEGO , Oct. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that Nasdaq has ...

  • PR Newswire5 months ago

    Aethlon Medical Announces Pricing of $6 Million Public Offering

    SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announces the pricing of a public offering of an aggregate of 5,454,546 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • PR Newswire5 months ago

    Aethlon Medical Receives National Cancer Institute Contract Award

    The NCI Phase I contract period runs from September 15, 2017 and runs through June 14, 2018.  The total amount of the firm fixed price contract is $299,250.  The contract calls for two subcontractors to work with the Company. The subcontractors under Aethlon Medical on the contract are University of Pittsburgh and Massachusetts General Hospital. Aethlon Medical is investigating the potential use of the Aethlon Hemopurifier® to reduce the presence of circulating tumor-derived exosomes (oncosomes), which contribute to cancer progression.  The Hemopurifier® is currently being advanced to treat life-threatening viral infections under an FDA designated Expedited Access Pathway (EAP) program.